Trial Profile

A STELLA observational study of AAVB-039

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AAVB 039 (Primary)
Indications Stargardt disease
Focus Adverse reactions
Acronyms STELLA

Most Recent Events

13 Nov 2025 New trial record
03 Nov 2025 According to AAVantgarde Bio media release, the company has successfully closed a $141 million Series B financing round, which will support this study.
02 Oct 2025 According to an AAVantgarde Bio media release, company continue recruiting in STELLA observational study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com